Mentions
Extended reach
Total likes
Video views
AI synopsis
The overall sentiment emphasizes that the seroprevalence data reveals a much higher infection rate than reported, with many posts referencing the 59% global seroprevalence figure and noting that over two-thirds of humanity had contracted the virus. The use of words like 'underestimated' and phrases such as 'significant implications' reflect a tone of concern and recognition of the study’s importance for understanding the pandemic's true scope.
Most discussions acknowledge the study’s significance, emphasizing that actual infection rates are higher than reported cases, indicating consensus on the importance of seroprevalence data.
Posts demonstrate high curiosity, with many referencing global seroprevalence statistics, regional variations, and implications for herd immunity, reflecting strong engagement with the topic.
A substantial number of posts cite specific data, such as percentages of population with antibodies and methodological points, showing deep involvement and analysis of the study’s findings.
Discussions highlight the profound implications of underreported infection rates for public health policies and future pandemic management, indicating high perceived impact.
Yapılan çalışmalar derlenip analiz edildiğinde , pandeminin 2.5 yılı biterken dünya nüfusunun 2/3’ü COVID19 ‘a karşı antikora sahip,yani aşı ya da doğal yoldan karşılaştı Not; Kış dalgası sonrası yeni yepyeni bir varyant gelişmezse takviye dozlar .. https://t.co/tRiZGGHqfQ
So proud to be working with incredible people around the world on this. While there are >630 million #COVID19 cases reported to @WHO, the actual number of infections is in the billions. #ProudToBeWHO working with everyone everywhere to end the pandemic
In a systematic review and meta analysis, Isabel Bergeri, Mairead Whelan, Harriet Ware, Lorenzo Subissi, and colleagues study global SARS-CoV-2 seroprevalence, two years into the COVID-19 pandemic. https://t.co/IqV7XLq4v4 @mvankerkhove #SystematicReview #COVID19 https://t.co/aFXqIDkgUj
Global SARS-CoV-2 seroprevalence from January 2020 to April 2022: A systematic review and meta-analysis of standardized population-based studies | PLOS Medicine https://t.co/wRpmf10UXY
"Des données de séroprévalence sont essentielles pour éclairer la prise de décision en matière de santé publique, en particulier dans les régions à faible capacité de test et de faibles taux de vaccination", concluent les auteurs. 5/5
Interesting WHO global seroprevalence study for SARS-CoV-2 Nice to see WHO is building on the seroprevalence work carried out by @mvankerkhove et al during the 2009 influenza pandemic https://t.co/QSkENIjvEG
This systematic review and meta-analysis assess the global spread of SARS-CoV-2 from January 2020 to April 2022, highlighting the true burden of infection across populations based on standardized studies.
This systematic review and meta-analysis examine SARS-CoV-2 antibody prevalence worldwide from January 2020 to April 2022, providing insights into population immunity levels during the pandemic.
@rdmorris @AeonCoin @DrJBhattacharya 1/2 Ah, that's from @zorinaq. Prevalence was typically lower for the elderly vs. for the middle-aged in wealthier nations. https://t.co/J0N3BjQar8 https://t.co/ppayIWCA5L https://t.co/gYLZTcuBu6 https://t.co/QVWlKJ6GvZ ... USA (national): https://t.co/VUysMFVZE4 https://t.co/C6N2bM6vLg
@FrankfurtZack Seroprävalenz lag bei +/-0 Anfang 2020 und stieg erst maßgeblich im Laufe von 2020 und 21 an Weltweit https://t.co/31TmyVTGWZ https://t.co/oRQEDgKug0
@FadingWolf @kim_because @Michael86612352 @moderateRepand1 @jackdoranjr @Kathy_Arizona @RAWONE420 @AngryFleas @RStabb26 @Vickie627 @Pineappleberry @valkyrie_rebel @Natural_Femme @FemmeVoilet @youknow714 @AgainMothra @EnragedApostate @metalbaby2u @JimlikesBB @EarthOne_13 @IanB_67 @EZembeck @JenniferAnn56 @teamphil @thereceipts33 @GarryConner6 @SheLady115 @sickathehighhat @Rebel__Hare @TelfordMk4 @StirredCrazy @mgdmd1 @OGLadymongoose @seleln1 @LokeyMJB @EricR42 @Observer254 @MJB24681 @hwollenwebber @GOP @FVAP @GovWolf @cspan @nbc @nytimes @CNN @mirandadevine @wef While also again... https://t.co/q9edsZjRwO
RT @PagetPhd: Moving to an environment where SARS-CoV-2 becomes endemic 'By September, 2021, global SARS-CoV-2 seroprevalence was estimate…
RT @PagetPhd: Moving to an environment where SARS-CoV-2 becomes endemic 'By September, 2021, global SARS-CoV-2 seroprevalence was estimate…
Moving to an environment where SARS-CoV-2 becomes endemic 'By September, 2021, global SARS-CoV-2 seroprevalence was estimated at 59%, with substantial variation in the proportion of immunity induced by infection or vaccination in different settings' https://t.co/eCRa58tcTY
Global SARS-CoV-2 seroprevalence from January 2020 to ... https://t.co/Nrs3xTEh4K
Global SARS-CoV-2 seroprevalence from January 2020 to April 2022: "Estimates of COVID-19 infections based on seroprevalence data far exceed reported cases" https://t.co/MZZYPBS8jC
@DrJBhattacharya This study suggest, that global infection rates were underestimated significantly? Sounds interesting in this context? "Currently, our global estimates of infections based on seroprevalence far exceed reported cases captured by surveillance systems." https://t.co/CkEopVVBOn
@DrJBhattacharya This study suggest, that global infection rates were underestimated significantly? Sounds interesting in this context? "Currently, our global estimates of infections based on seroprevalence far exceed reported cases captured by surveillance systems." https://t.co/CkEopVVBOn
RT @TimLaheyMD: More than a third of us are still SARS-CoV-2 seronegative HT @glassmanamanda https://t.co/g7oRjtlFmP https://t.co/jWSN3Fni…
By September 2021, global #SARSCoV2 seroprevalence from infection or vaccination was 59.2%, 95% CI [56.1% to 62.2%]. No #Herdimmunity whatsoever. https://t.co/Fpy3djKK6i
RT @TimLaheyMD: More than a third of us are still SARS-CoV-2 seronegative HT @glassmanamanda https://t.co/g7oRjtlFmP https://t.co/jWSN3Fni…
More than a third of us are still SARS-CoV-2 seronegative HT @glassmanamanda https://t.co/g7oRjtlFmP https://t.co/jWSN3FniF1
RT @glassmanamanda: “After the emergence of Omicron in March 2022, infection-induced seroprevalence rose to 47.9% [41.0% to 54.9%] in Europ…
“After the emergence of Omicron in March 2022, infection-induced seroprevalence rose to 47.9% [41.0% to 54.9%] in Europe HIC and 33.7% [31.6% to 36.0%] in Americas HIC.” (Ie, still plenty of immunologically naive) https://t.co/iIoRBsiXYE
RT @Epiconcept: #FRIDAYREAD New article published: "Global SARS-CoV-2 seroprevalence from January 2020 to April 2022: A systematic review a…
RT @medical_xpress: Global COVID-19 #infection rates may be higher than previously reported @plosmedicine https://t.co/EC3fiRXZDX https://t…
2/2 https://t.co/krYidjWMhr
#FRIDAYREAD New article published: "Global SARS-CoV-2 seroprevalence from January 2020 to April 2022: A systematic review and meta-analysis of standardized population-based studies" @WHO #epidemiology #Covid19 #SARSCov2 #seroprelalence 1/2
RT @naif_khalaf: Global SARS-CoV-2 seroprevalence from January 2020 to April 2022: A systematic review and meta-analysis of standardized po…
Global SARS-CoV-2 seroprevalence from January 2020 to April 2022: A systematic review and meta-analysis of standardized population-based studies | PLOS Medicine https://t.co/wRpmf10UXY
Global SARS-CoV-2 seroprevalence from January 2020 to April 2022: A systematic review and meta-analysis of standardized population-based studies | PLOS Medicine https://t.co/fITOqoVtYg
RT @PagetPhd: Interesting WHO global seroprevalence study for SARS-CoV-2 Nice to see WHO is building on the seroprevalence work carried ou…
Global seroprevalence of SARS-CoV-2 from January 2020 to April 2022 ... | #COVID19 | #variants | #SARSCoV2 | #virus | #mutants | Via @NewsMedical https://t.co/KwcZfxMPB5
Nearly entire European population had anti-SARS-CoV-2 antibodies in early 2022. @C_A_Gustave H/t @nicolasberrod Global SARS-CoV-2 seroprevalence from January 2020 to April 2022: A systematic review and meta-analysis of standardized population-based studies https://t.co/qiaFlDJOUy
RT @PagetPhd: Interesting WHO global seroprevalence study for SARS-CoV-2 Nice to see WHO is building on the seroprevalence work carried ou…
RT @PagetPhd: Interesting WHO global seroprevalence study for SARS-CoV-2 Nice to see WHO is building on the seroprevalence work carried ou…
Interesting WHO global seroprevalence study for SARS-CoV-2 Nice to see WHO is building on the seroprevalence work carried out by @mvankerkhove et al during the 2009 influenza pandemic https://t.co/QSkENIjvEG
"Des données de séroprévalence sont essentielles pour éclairer la prise de décision en matière de santé publique, en particulier dans les régions à faible capacité de test et de faibles taux de vaccination", concluent les auteurs. 5/5
Global seroprevalence has risen considerably over time and with regional variation; however, over one-third of the global population are seronegative to SARS-CoV-2. Study estimates of infections based on seroprevalence far exceed reported Covid-19 cases. https://t.co/i1eHkFkpR6 https://t.co/1jYBsZl6N6
What was the global SARS-CoV-2 seroprevalence from January 2020 to April 2022? #MedPub #PharmaTwitter #MedEd #Pharmaceuticals https://t.co/I2alefjz7d
What was the global SARS-CoV-2 seroprevalence from January 2020 to April 2022? https://t.co/cMPELHfGU7
What was the global SARS-CoV-2 seroprevalence from January 2020 to April 2022? #MedPub #PulmoTwitter #MedEd #Pulmonology https://t.co/mgnspgMi3q
What was the global SARS-CoV-2 seroprevalence from January 2020 to April 2022? https://t.co/UBnGVHwft9 @WHO #SARSCoV2 #COVID19 #Seroprevalence https://t.co/mrsGx1yHbo
RT @PLOSMedicine: In a systematic review and meta analysis, Isabel Bergeri, Mairead Whelan, Harriet Ware, Lorenzo Subissi, and colleagues s…
RT @mvankerkhove: So proud to be working with incredible people around the world on this. While there are >630 million #COVID19 cases repor…
RT @PLOSMedicine: In a systematic review and meta analysis, Isabel Bergeri, Mairead Whelan, Harriet Ware, Lorenzo Subissi, and colleagues s…
RT @PLOSMedicine: In a systematic review and meta analysis, Isabel Bergeri, Mairead Whelan, Harriet Ware, Lorenzo Subissi, and colleagues s…
RT @PLOSMedicine: In a systematic review and meta analysis, Isabel Bergeri, Mairead Whelan, Harriet Ware, Lorenzo Subissi, and colleagues s…
RT @PLOSMedicine: In a systematic review and meta analysis, Isabel Bergeri, Mairead Whelan, Harriet Ware, Lorenzo Subissi, and colleagues s…
RT @PLOSMedicine: In a systematic review and meta analysis, Isabel Bergeri, Mairead Whelan, Harriet Ware, Lorenzo Subissi, and colleagues s…
RT @PLOSMedicine: In a systematic review and meta analysis, Isabel Bergeri, Mairead Whelan, Harriet Ware, Lorenzo Subissi, and colleagues s…
RT @PLOSMedicine: In a systematic review and meta analysis, Isabel Bergeri, Mairead Whelan, Harriet Ware, Lorenzo Subissi, and colleagues s…
@lyndsy11993653 @KimKimH @lisa_iannattone [Nov 10 2022] Peer-reviewed meta-analysis: Global SARS-CoV-2 seroprevalence reveals almost 2/3rds of humanity had a Covid infection by April 2022 https://t.co/xMFTr3FcRZ
RT @PLOSMedicine: In a systematic review and meta analysis, Isabel Bergeri, Mairead Whelan, Harriet Ware, Lorenzo Subissi, and colleagues s…
RT @PLOSMedicine: In a systematic review and meta analysis, Isabel Bergeri, Mairead Whelan, Harriet Ware, Lorenzo Subissi, and colleagues s…
RT @PLOSMedicine: In a systematic review and meta analysis, Isabel Bergeri, Mairead Whelan, Harriet Ware, Lorenzo Subissi, and colleagues s…
RT @PLOSMedicine: In a systematic review and meta analysis, Isabel Bergeri, Mairead Whelan, Harriet Ware, Lorenzo Subissi, and colleagues s…
RT @PLOSMedicine: In a systematic review and meta analysis, Isabel Bergeri, Mairead Whelan, Harriet Ware, Lorenzo Subissi, and colleagues s…
RT @PLOSMedicine: In a systematic review and meta analysis, Isabel Bergeri, Mairead Whelan, Harriet Ware, Lorenzo Subissi, and colleagues s…
In a systematic review and meta analysis, Isabel Bergeri, Mairead Whelan, Harriet Ware, Lorenzo Subissi, and colleagues study global SARS-CoV-2 seroprevalence, two years into the COVID-19 pandemic. https://t.co/IqV7XLq4v4 @mvankerkhove #SystematicReview #COVID19 https://t.co/aFXqIDkgUj
RT @esenol: Yapılan çalışmalar derlenip analiz edildiğinde , pandeminin 2.5 yılı biterken dünya nüfusunun 2/3’ü COVID19 ‘a karşı antikora s…
Global SARS-CoV-2 seroprevalence from January 2020 to April 2022: A systematic review and meta-analysis of standardized population-based studies https://t.co/KvDCct94CS
RT @esenol: Yapılan çalışmalar derlenip analiz edildiğinde , pandeminin 2.5 yılı biterken dünya nüfusunun 2/3’ü COVID19 ‘a karşı antikora s…
Die Infektionsrate bei #COVID19 wurde unterschätzt. D.h. Seroprevalenz ist höher als gedacht. Auf dem Weg in die Endemie. #pandemie #ImpfenSchuetzt #corona #omikron #epidemiologie https://t.co/cZJ67mTBcX
RT @mvankerkhove: So proud to be working with incredible people around the world on this. While there are >630 million #COVID19 cases repor…
RT @EmMicucci: #Covid #Oms: Entro settembre 2021 il 59,2% della popolaz globale era sieropositivo per infezione o vaccino. Era solo 7,7% a…
RT @esenol: Yapılan çalışmalar derlenip analiz edildiğinde , pandeminin 2.5 yılı biterken dünya nüfusunun 2/3’ü COVID19 ‘a karşı antikora s…
RT @mvankerkhove: So proud to be working with incredible people around the world on this. While there are >630 million #COVID19 cases repor…
RT @esenol: Yapılan çalışmalar derlenip analiz edildiğinde , pandeminin 2.5 yılı biterken dünya nüfusunun 2/3’ü COVID19 ‘a karşı antikora s…
RT @esenol: Yapılan çalışmalar derlenip analiz edildiğinde , pandeminin 2.5 yılı biterken dünya nüfusunun 2/3’ü COVID19 ‘a karşı antikora s…
RT @mvankerkhove: So proud to be working with incredible people around the world on this. While there are >630 million #COVID19 cases repor…
RT @johnjljacobs: SARS-CoV-2 seroprevelance
RT @johnjljacobs: SARS-CoV-2 seroprevelance
SARS-CoV-2 seroprevelance
On serological surveillance for #SARSCoV2 #COVID http://doi.org/10.1371/journal.pmed.1004107 http://doi.org/10.1371/journal.pmed.1004132
On serological surveillance for #SARSCoV2 #COVID https://t.co/Mipo64KCMG https://t.co/ki8dYIYymI
#Covid #Oms: Entro settembre 2021 il 59,2% della popolaz globale era sieropositivo per infezione o vaccino. Era solo 7,7% a giugno 2020 "Stime infezioni da #covid basate sui dati sieroprevalenza superano di gran lunga i casi segnalati" Via PLOS Medicine https://t.co/WM3NEYdAHB
RT @RolandBakerIII: PLOS: Global SARS-CoV-2 seroprevalence from January 2020 to April 2022: A systematic review and meta-analysis of standa…
RT @esenol: Yapılan çalışmalar derlenip analiz edildiğinde , pandeminin 2.5 yılı biterken dünya nüfusunun 2/3’ü COVID19 ‘a karşı antikora s…
RT @mvankerkhove: So proud to be working with incredible people around the world on this. While there are >630 million #COVID19 cases repor…
RT @mvankerkhove: So proud to be working with incredible people around the world on this. While there are >630 million #COVID19 cases repor…
RT @esenol: Yapılan çalışmalar derlenip analiz edildiğinde , pandeminin 2.5 yılı biterken dünya nüfusunun 2/3’ü COVID19 ‘a karşı antikora s…
RT @esenol: Yapılan çalışmalar derlenip analiz edildiğinde , pandeminin 2.5 yılı biterken dünya nüfusunun 2/3’ü COVID19 ‘a karşı antikora s…
RT @esenol: Yapılan çalışmalar derlenip analiz edildiğinde , pandeminin 2.5 yılı biterken dünya nüfusunun 2/3’ü COVID19 ‘a karşı antikora s…
RT @esenol: Yapılan çalışmalar derlenip analiz edildiğinde , pandeminin 2.5 yılı biterken dünya nüfusunun 2/3’ü COVID19 ‘a karşı antikora s…
Yapılan çalışmalar derlenip analiz edildiğinde , pandeminin 2.5 yılı biterken dünya nüfusunun 2/3’ü COVID19 ‘a karşı antikora sahip,yani aşı ya da doğal yoldan karşılaştı Not; Kış dalgası sonrası yeni yepyeni bir varyant gelişmezse takviye dozlar .. https://t.co/tRiZGGHqfQ
RT @jlerollblues: Where we are, good meta study: "Routine surveillance data underestimate infection and cannot infer on population immunity…
Where we are, good meta study: "Routine surveillance data underestimate infection and cannot infer on population immunity; there is a predominance of asymptomatic infections, and uneven access to diagnostics." @PeterHotez @DrEricDing @mtosterholm https://t.co/y1qZ8s7gPe
RT @mvankerkhove: So proud to be working with incredible people around the world on this. While there are >630 million #COVID19 cases repor…
PLOS: Global SARS-CoV-2 seroprevalence from January 2020 to April 2022: A systematic review and meta-analysis of standardized population-based studies: Two thirds of the world's population has SARS-CoV-2 antibodies. https://t.co/8BTdrHylzI
RT @mvankerkhove: So proud to be working with incredible people around the world on this. While there are >630 million #COVID19 cases repor…
RT @mvankerkhove: So proud to be working with incredible people around the world on this. While there are >630 million #COVID19 cases repor…
Global SARSCoV2 seroprevalence from January 2020 to April 2022: systematic review & meta-analysis: Sept 2021, global SARSCoV2 seroprevalence from infection or vac was 59.2%; https://t.co/eH0EMdoQ9z
Global SARS-CoV-2 seroprevalence from January 2020 to April 2022: A systematic review and meta-analysis of standardized population-based studies https://t.co/EMhSegtYc5
RT @mvankerkhove: So proud to be working with incredible people around the world on this. While there are >630 million #COVID19 cases repor…
Global SARS-CoV-2 seroprevalence from January 2020 to April 2022: A systematic review and meta-analysis of standardized population-based studies https://t.co/eXeHZzuNtN
RT @mvankerkhove: So proud to be working with incredible people around the world on this. While there are >630 million #COVID19 cases repor…
RT @mvankerkhove: So proud to be working with incredible people around the world on this. While there are >630 million #COVID19 cases repor…
So proud to be working with incredible people around the world on this. While there are >630 million #COVID19 cases reported to @WHO, the actual number of infections is in the billions. #ProudToBeWHO working with everyone everywhere to end the pandemic
Proud to co-first author this huge work with a great team. We found 59% of the world has antibodies against COVID-19 as of Q3 2021, confirmed cases were underestimated by 10:1 #PLOSMedicine Global SARS-CoV-2 seroprevalence from January 2020 to April 2022 https://t.co/xhZnb2EE05
RT @medical_xpress: Global COVID-19 #infection rates may be higher than previously reported @plosmedicine https://t.co/EC3fiRXZDX https://t…
Global COVID-19 #infection rates may be higher than previously reported @plosmedicine https://t.co/EC3fiRXZDX https://t.co/qBgeZkodGN
U
J